Beyond the Endpoint: Industry Voices Reflect on Compass’ Phase 3 Readout - Psychedelic Alpha analysis of COMP360 topline reaction

Psilocybin in Compass Pathways' Phase 3 COMP360 program for treatment-resistant depression sparks mixed industry reaction after a topline readout. Industry and investor commentary focuses on efficacy expectations versus the trial's primary endpoint: some investors view the week 6 MADRS delta as underwhelming, while others stress that meeting the primary endpoint and seeing a positive safety signal still matters in a difficult population. The article highlights that the market is watching what comes next, including longer-term follow-up for COMP005 and multi-dose results for COMP006, as potential proof for commercial value. Durability and dosing are presented as the key differentiators for COMP360's commercial case, with discussion of potential sales forecasts and comparisons to other depression interventions. Broader themes include how incentives, politics, and a shifting regulatory climate shape industry interpretations of psychedelics trial data.